Agreed. Buyout might occur on positive human trial data vs. competitive treatments alone. Either way, it would be long after IDE approval. Upon IDE approval, RDGL has to peddle another offering to fund trials (which should close very quickly), pay Mayo to design trial, Mayo has to recruit patients, conduct trail, etc.
News 
Market Data 
Discover 
